Research
Long-form, observational analysis of category-level shifts in the women's health economy.
The rise of transition-specific healthcare
Why care models organized around life-stage transitions — not single conditions — are becoming the default in women's health.
The Index Editorial·
From a vertical to a structural layer of healthcare: how the category is being rebuilt as infrastructure.
The Index Editorial·
How at-home diagnostics rewired the entry point to women's healthcare.
The Index Editorial·
An observational read on where hormonal health is heading — clinically and structurally.
The Index Editorial·
The cultural turn toward longevity is changing what women buy, how they screen, and how they relate to clinicians.
The Index Editorial·
How the menopause category went from invisible to a multi-billion-dollar formation in less than five years.
The Index Editorial·Integrated Benefits Institute analysis of 1,001 employed US women finds benefit utilization linked to higher retention and 89% job-satisfaction lift.
The Index Editorial·
March of Dimes documents counties with no obstetric providers and rising infant mortality in rural and low-income communities.
The Index Editorial·JAMA Network Open serial cross-sectional Kaiser Permanente study finds PPD rates increased across all groups 2010-2021; Black and multiracial women bear highest burden.
The Index Editorial·BMC Psychiatry meta-analysis of 50 studies / 385,092 women finds 28.0% pooled global prevalence of depression in postmenopausal women.
The Index Editorial·NCHS / CDC Health E-Stat 113: 649 maternal deaths in 2024; Black non-Hispanic rate 44.8 (3.1× White rate); women 40+ at 62.3 per 100,000.
The Index Editorial·
Commonwealth Fund: US maternal mortality ratio 22.3 per 100,000 — highest among 18 high-income peers, 10× Norway's rate.
The Index Editorial·
JACC pooled STEP-HFpEF analysis (n=1,145; 49.7% women): semaglutide produces greater weight loss in women (-9.6%) than men (-7.2%); symptom gains equal.
The Index Editorial·JACC prespecified sex-stratified analysis: semaglutide 2.4mg consistently reduces MACE in both sexes; women face higher baseline CV risk at equivalent BMI.
The Index Editorial·
GeroScience publication: Tally Health's CheekAge predicts all-cause mortality and tracks with lifestyle factors via cheek-swab DNA methylation.
The Index Editorial·JAMA 2024 review synthesizes 20+ years of WHI follow-up: in the timing-hypothesis window (<10 yrs from menopause or <60), MHT shows no significant rise in all-cause mortality and a possible benefit for estrogen-alone in younger women.
The Index Editorial·